Advanced search

Serotonin related genes affect antidepressant treatment in obsessive-compulsive disorder

Author
Organization
Abstract
Up to 60% of OCD patients do not respond to a regular serotonin reuptake inhibitor (SRI) treatment. The purpose of the present study was to determine whether polymorphisms of the serotonin transporter (5-HTT), 5-HT1Dβ, and 5-HT2A receptor genes affect the efficacy of SRI treatment in OCD. Ninety-one outpatients with primary OCD according to DSM-IV criteria consented to the study were randomly assigned a 12-week, double-blind trial to receive dosages titrated upward to 300 mg/day of venlafaxine, or 60 mg/day of paroxetine. Primary efficacy was assessed by the change from baseline on the Yale-Brown obsessive–compulsive scale (Y-BOCS), and response was defined as a [greater-than-or-equal]25% reduction on the Y-BOCS. All of the paroxetine treated patients, with the G/G genotype of the 5-HT2A polymorphism were responders (χ2 = 8.66, df = 2, p = 0.013). In the venlafaxine treated patients, the majority of responders carried the S/L genotype of the 5-HTTLPR polymorphism (χ2 = 9.71, df = 2, p = 0.008). The small group of patients who both carried the S/L genotype of the 5-HTTLPR polymorphism and the G/G genotype of the 5-HT2A polymorphism responded all to treatment. The results of this study suggest that the response in paroxetine and in venlafaxine treated OCD patients is associated with the G/G genotype of the 5-HT2A polymorphism and with the S/L genotype of the 5-HTTLPR polymorphism, respectively.

Citation

Please use this url to cite or link to this publication:

Chicago
Van Nieuwerburgh, Filip, Dieter Deforce, and Damiaan Denys. 2008. “Serotonin Related Genes Affect Antidepressant Treatment in Obsessive-compulsive Disorder.” In Progress in Neurotherapeutics and Neuropsychopharmacology, ed. Jeffrey Cummings, 3(1):227–240. Cambridge: Cambridge University Press.
APA
Van Nieuwerburgh, Filip, Deforce, D., & Denys, D. (2008). Serotonin related genes affect antidepressant treatment in obsessive-compulsive disorder. In J. Cummings (Ed.), Progress in Neurotherapeutics and Neuropsychopharmacology (Vol. 3(1), pp. 227–240). Cambridge: Cambridge University Press.
Vancouver
1.
Van Nieuwerburgh F, Deforce D, Denys D. Serotonin related genes affect antidepressant treatment in obsessive-compulsive disorder. In: Cummings J, editor. Progress in Neurotherapeutics and Neuropsychopharmacology. Cambridge: Cambridge University Press; 2008. p. 227–40.
MLA
Van Nieuwerburgh, Filip, Dieter Deforce, and Damiaan Denys. “Serotonin Related Genes Affect Antidepressant Treatment in Obsessive-compulsive Disorder.” Progress in Neurotherapeutics and Neuropsychopharmacology. Ed. Jeffrey Cummings. Vol. 3(1). Cambridge: Cambridge University Press, 2008. 227–240. Print.
@incollection{671383,
  abstract     = {Up to 60\% of OCD patients do not respond to a regular serotonin reuptake inhibitor (SRI) treatment. The purpose of the present study was to determine whether polymorphisms of the serotonin transporter (5-HTT), 5-HT1D\ensuremath{\beta}, and 5-HT2A receptor genes affect the efficacy of SRI treatment in OCD. Ninety-one outpatients with primary OCD according to DSM-IV criteria consented to the study were randomly assigned a 12-week, double-blind trial to receive dosages titrated upward to 300 mg/day of venlafaxine, or 60 mg/day of paroxetine. Primary efficacy was assessed by the change from baseline on the Yale-Brown obsessive--compulsive scale (Y-BOCS), and response was defined as a [greater-than-or-equal]25\% reduction on the Y-BOCS. All of the paroxetine treated patients, with the G/G genotype of the 5-HT2A polymorphism were responders (\ensuremath{\chi}2 = 8.66, df = 2, p = 0.013). In the venlafaxine treated patients, the majority of responders carried the S/L genotype of the 5-HTTLPR polymorphism (\ensuremath{\chi}2 = 9.71, df = 2, p = 0.008). The small group of patients who both carried the S/L genotype of the 5-HTTLPR polymorphism and the G/G genotype of the 5-HT2A polymorphism responded all to treatment.

The results of this study suggest that the response in paroxetine and in venlafaxine treated OCD patients is associated with the G/G genotype of the 5-HT2A polymorphism and with the S/L genotype of the 5-HTTLPR polymorphism, respectively.},
  author       = {Van Nieuwerburgh, Filip and Deforce, Dieter and Denys, Damiaan},
  booktitle    = {Progress in Neurotherapeutics and Neuropsychopharmacology},
  editor       = {Cummings, Jeffrey},
  issn         = {1748-2321},
  language     = {eng},
  pages        = {227--240},
  publisher    = {Cambridge University Press},
  series       = {Progress in Neurotherapeutics and Neuropsychopharmacology},
  title        = {Serotonin related genes affect antidepressant treatment in obsessive-compulsive disorder},
  url          = {http://dx.doi.org/10.1017/S1748232107000146},
  volume       = {3(1)},
  year         = {2008},
}

Altmetric
View in Altmetric